Spectrum Pharmaceuticals Strengthens Commercial Operations with Appointment of Brian Holzer MD, MBA as Executive Director

  • Biotechnology Professional with Significant Experience in Hematology/Oncology Strategy and Marketing
  • Joins Spectrum from Amgen, Where He Was the Director of United States Strategy and Operations for the NEUPOGEN®/Neulasta®, Multi-Billion Dollar Worldwide Franchise

HENDERSON, Nev.--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGS:SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced the appointment of Brian Holzer to the position of Executive Director of Brand Management. Dr. Holzer will report to Rick Gonzalez, Vice President of Business Solutions and Government Affairs. He will be primarily responsible for leading and managing Spectrum’s cross-functional brand efforts for FUSILEV® and ZEVALIN® as well as brand planning for apaziquone and belinostat, Spectrum’s late-stage drugs in development.

“We believe Dr. Holzer will be an immediate value-added member of the Spectrum Pharmaceuticals commercial organization as we continue to grow the FUSILEV and ZEVALIN brands and prepare for the additions of apaziquone and belinostat over the next 12-18 months,” said Rajesh C. Shrotriya, MD, Chairman, Chief Executive Officer, and President of Spectrum Pharmaceuticals. “We believe Brian’s education in medicine and business administration, along with his hands on experience in successfully building on a hematology/oncology franchise at Amgen with regard to NEUPOGEN®/Neulasta® will have an immediate positive impact on our commercial organization.”

Dr. Holzer comes to Spectrum with significant experience in the health care industry and a proven track record of high performance. At Amgen, he was most recently the Director of Strategy and Operations for the NEUPOGEN®/Neulasta® franchise in the Oncology Business Unit, and primarily was responsible for brand planning, budget management, and data analytics. Previously, Brian held positions of increasing responsibility on the NEUPOGEN/Neulasta® promotions team and was a key contributor to innovative branded and unbranded marketing campaigns. Brian started his tenure at Amgen as a sales representative for Enbrel® in the New York/New Jersey metro area.

Dr. Holzer earned his Bachelor of Science in General Science from Pennsylvania State University, his MD from the Drexel School of Medicine and his MBA from The Wharton School of Business with a focus in Health Care Management. Prior to Wharton, Brian worked as a medical resident in the University of Pennsylvania Health System before joining the Reed Smith law firm as an internal medical consultant on pharmaceutical litigation cases including Prempro® and Vioxx®.

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology. The Company’s strategy is comprised of acquiring, developing and commercializing a broad and diverse pipeline of late-stage clinical and commercial products. The Company markets two oncology drugs, FUSILEV and ZEVALIN and has two drugs, apaziquone and belinostat, in late stage development along with a diversified pipeline of novel drug candidates. The Company has assembled an integrated in-house scientific team, including clinical development, medical research, regulatory affairs, biostatistics and data management, formulation development, and has established a commercial infrastructure for the marketing of its drug products. The Company also leverages the expertise of its worldwide partners to assist in the execution of its strategy. For more information, please visit the Company’s website at www.sppirx.com.

Forward-looking statement – This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management’s current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees, around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates, may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA, and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of revenues, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.

SPECTRUM PHARMACEUTICALS, INC. ®, ZEVALIN®, and FUSILEV® are registered trademarks of Spectrum Pharmaceuticals, Inc. REDEFINING CANCER CARE™ and the Spectrum Pharmaceutical logos are trademarks owned by Spectrum Pharmaceuticals, Inc.

© 2011 Spectrum Pharmaceuticals, Inc. All Rights Reserved.



CONTACT:

Spectrum Pharmaceuticals
Paul Arndt
Senior Manager, Investor Relations
702-835-6300

KEYWORDS:   United States  North America  Nevada

INDUSTRY KEYWORDS:   Health  Biotechnology  Oncology  Pharmaceutical  Professional Services  Finance

MEDIA:

Logo
 Logo

Suggested Articles

Helsinn Group and MEI Pharma penned a near $500 million biobucks pact for experimental blood cancer drug pracinostat back in 2016.

Novavax has brought new CMC head Machielse to head manufacturing; Rexgenero taps Wagener as CMO; EMA nominates Cooke as new director.

The deal grants Sarepta the exclusive right to use Hansa Biopharma’s imlifidase to eliminate neutralizing antibodies in DMD and LGMD patients.